Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals Inc (NQ: ELDN )

2.060 +0.040 (+1.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 81,544
Open 2.050
Bid (Size) 2.010 (20)
Ask (Size) 2.090 (1)
Prev. Close 2.020
Today's Range 2.000 - 2.080
52wk Range 1.070 - 2.950
Shares Outstanding 22,506,956
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
+9.57%
+9.57%
1 Month
N/A
N/A
3 Month
+10.75%
+10.75%
6 Month
+30.38%
+30.38%
1 Year
-1.90%
-1.90%

More News

Read More
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Expert Ratings for Eledon Pharma
Via Benzinga
Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive
Via Benzinga
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.